Showing 31-40 of 50 results for "".
- The National Eczema Association Names Amy Fauver New VP For Advocacy & Accesshttps://practicaldermatology.com/news/the-national-eczema-association-names-amy-fauver-new-vp-for-advocacy-access/2458872/The National Eczema Association (NEA) named Amy Fauver as Vice President for Advocacy and Access. The NEA says in this new position, Ms. Fauver will build its advocacy capacity and better leverage the voices of the eczema community, enhancing NEA’s ability to create meaningful changes in ec
- Skin Cancer Foundation Inducts Dr. Amy Forman Taub into its Amonette Circlehttps://practicaldermatology.com/news/20130327-skin_cancer_foundation_inducts_amy_forman_taub_md_into_its_amonette_circle/2459579/Amy Forman Taub, MD, was recently inducted into the Skin Cancer Foundation's Amonette Circle at the American Academy of Dermatology Annual Meeting in Miami, FL. Amonette Circle is a lifetime membership comprised of physicians who make an outstanding commitment to The Skin Cancer Foundation's mission
- Chicago Dermatologist Dr. Amy S. Paller Wins American Skin Association’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/chicago-dermatologist-dr-amy-s-paller-wins-american-skin-associations-david-martin-carter-mentor-award/2460802/Amy S. Paller, MD of the Feinberg School of Medicine at Northwestern University in Chicago received the American Skin Association's David Martin Carter Mentor Award. For more than three decades, ASA's David Martin Carter Mentor Award has honored members of th
- L'Oréal's SkinCeuticals USA Appoints Angela Hildebrand as General Managerhttps://practicaldermatology.com/news/loreals-skinceuticals-usa-appoints-angela-hildebrand-as-general-manager/2461975/Angela Hildebrand is SkinCeuticals’ new General Manager and Amy Sloan is the Senior Vice President of Business Strategy and Growth. "With their collective knowledge, expertise, and dedication to excellence, Angela and Amy's leadership are poised to tak
- Sun Safety Day at Wrigley a Success for Sun Heroeshttps://practicaldermatology.com/news/sun-safety-day-at-wrigley-a-success-for-sun-heroes/2461261/As an extension of the Sun Heroes initiative, CeraVe's Sun Safety Day at Wrigley Field in partnership with Amy Brodsky, MD brought sun protection education to attendees as the Chicago Cubs hosted the Atlanta Braves. Dr. Brodsky founded
- Calling All Dermatologists: The Sun Heroes Initiative Wants You to Become a Herohttps://practicaldermatology.com/news/calling-all-dermatologists-the-sun-heroes-initiative-wants-you-to-help-bring-sun-safety-programs-to-elementary-schools/2461232/CeraVe and L'Oreal Dermatological Beauty brand La Roche-Posay are teaming up with dermatologist Amy Brodsky, MD to bring sun safety programs to elementary schools around the country. Sun Heroes is an educational program that equips healthcare professionals with
- Leadership Changes Take Place at SkinCeuticalshttps://practicaldermatology.com/news/leadership-changes-at-skinceuticals/2461069/Stephanie Kramer is now SkinCeutical’s Global General Manager, and Amy Sloan is the Head of SkinCeuticals U.S, the company reports Sloan brings 15 years of global and U.S. beauty industry experience - 10 of those years with SkinCeuticals - to the role of Head o
- Neauvia’s Introduces Zaffiro, A Two-Part Solution to Skin Rejuvenationhttps://practicaldermatology.com/news/neuvias-introduces-zaffiro-a-two-part-solution-to-skin-rejuvenation/2460305/Neauvia introduced Zaffiro to the media at an event held in New York City’s Hudson Yards, featuring New York City dermatologist Amy Lewis, MD Launched in the US in late 2019, the Zaffiro device is a dual facial rejuve
- Investigational Cannabinoid Receptor Agonist Proves Safe and Effective in Amyopathic Dermatomyositishttps://practicaldermatology.com/news/investigational-cannabinoid-receptor-agonist-proves-safe-and-effective-in-amyopathic-dermatomyositis/2461357/Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis, a new study in the Journal of Investigative Dermatology suggests. This phase 2 trial, the
- Amytrx Therapeutics Raises $18M for New AD Treatmenthttps://practicaldermatology.com/news/amytrx-therapeutics-raises-18m-for-new-ad-treatment/2461211/Amytrx Therapeutics closed on its final tranche of its Series A capital raise, totaling $18 million to expand on its clinical research investigating AMTX-100, a new cell- penetrating immune system modulating peptide therapeutic for topical skin applications, specifically in atopic derma